MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.97
-0.41
-4.89%
After Hours: 7.97 0 0.00% 16:00 07/14 EDT
OPEN
8.35
PREV CLOSE
8.38
HIGH
8.48
LOW
7.84
VOLUME
151.51K
TURNOVER
--
52 WEEK HIGH
11.38
52 WEEK LOW
3.500
MARKET CAP
355.41M
P/E (TTM)
-3.2913
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AGLE stock price target is 16.83 with a high estimate of 26.00 and a low estimate of 10.00.

EPS

AGLE News

More
Were Hedge Funds Right About Buying Aeglea BioTherapeutics, Inc. (AGLE)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 06/30 16:05
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)
Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 06/29 16:00
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
Zacks · 06/26 16:30
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%
Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks · 06/23 12:47
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
Is (AGLE) Outperforming Other Medical Stocks This Year?
Zacks · 06/10 15:30
Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick
Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks · 06/08 13:03
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
Zacks · 06/04 16:17
Aeglea BioTherapeutics to Present at BIO Digital 2020
AUSTIN, Texas, June 01, 2020 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as.
GlobeNewswire · 06/01 20:05

Industry

Biotechnology & Medical Research
+2.50%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About AGLE

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.
More

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.